Changes in meibum composition following plaque brachytherapy for choroidal melanoma

Aparna Ramasubramanian,1 Simra Fatima Ahmed,2 Douglas Borchman1 2

ABSTRACT

Objectives Dry eye is common when external beam radiation is used for the treatment of choroidal melanoma (CM). As meibum structure and composition have been related to dry eye, we determined if plaque brachytherapy for CM alters meibum composition.

Design 1H-NMR spectroscopy was used to measure the lipid composition of meibum.

Setting The University of Louisville, Kentucky, USA.

Participants All 13 participants had CM and one participant had iris melanoma.

Main outcome measures Cholesteryl ester (CE) to wax ester (WE) ratio, amount of meibum esters (ME) and meibum lipid saturation were measured.

Results ME decreased by 80%±18% (±99% CI) in 11 eyes that were treated compared with the contralateral untreated eye. ME increased by 181% in two eyes that were treated compared with the contralateral untreated eye. The mole % CE/WE for meibum was significantly (p<0.0001) 67% lower in eyes that were irradiated compared with the contralateral untreated eye. The mole % CE/WE for meibum from eyes that had plaque brachytherapy was 80% lower in 11 of 14 eyes compared with the contralateral eye.

Conclusion Eyes that had plaque brachytherapy had a lower amount of expressible meibum and a lower CE/WE ratio compared with meibum from the contralateral eye that received no treatment and eyes that did not have uveal melanoma. Both the quantity and quality of meibum should be considered in designing a therapy for dry eye after plaque brachytherapy.

INTRODUCTION

Uveal melanoma is the most common primary intraocular malignancy in adults. It most commonly originates in the choroid (90%) followed by the ciliary body (6%) and then iris (4%). Enucleation was the primary modality of treatment for uveal melanoma in the 1970s prior to the Collaborative Ocular Melanoma Study.1 This large multicentre trial demonstrated the safety of plaque brachytherapy with respect to long-term mortality and tumour control.1 Iodine-125 is the most commonly used radioisotope, and the American Brachytherapy Society recommends 0.60–1.05 Gy/hour over three to seven consecutive days.2

Dry eye is very common, 47%, when external beam radiation is used for the treatment of uveal melanoma.3 The incidence of dry eye was 24% when proton beam radiotherapy was used to treat uveal melanomas.4 Clinical dry eye is much less common with plaque brachytherapy in view of the localised radiation and the posterior location in choroidal melanoma. Dry eye was reported in 8.3% of patients at an average of 20.7 months after treatment.5 With respect to iris melanoma, only 2 out of 23 patients treated with ruthenium plaque had clinical dry eye. Even with the anterior location, the dry eye incidence was low, and it was postulated that the reason was that lacrimal gland and conjunctival goblet cells were not included in the field of irradiation, in contrast to proton beam...
therapy or stereotactic radiation. In contrast to this clinical study, histopathological evaluation of the conjunctiva following plaque brachytherapy suggested that epithelial stratification and distributional changes in ocular mucins could lead to development of dry eye.

Meibomian glands, which are sebaceous in nature, are more sensitive to irradiation and are more permanently altered than other sebaceous glands like glands of Zeis. Following external beam radiation, irreversible structural damage to the meibomian glands have been documented in patients with orbital lymphoma. Meibomian gland dysfunction (MGD) contributes to dry eye. The meibomian gland, located in the eye lids, produce meibum, the major source of tear film lipid layer. The TFLL contributes to tear film stability. The TFLL has been documented in patients with orbital lymphoma.

METHODS

Collection and processing of human meibum

Meibum was collected from 14 patients who underwent plaque brachytherapy for choroidal melanoma at the Department of Ophthalmology, the University of Louisville. Written informed consent was obtained from all donors. All procedures were in accord with the Declaration of Helsinki. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Meibomian glands were gently expressed by pressing the eyelid with a fingertip with strict attention to avoid touching the eyelid margin during expression. All four eyelids were expressed, and approximately 0.5 mg of meibum lipid was collected per individual for direct spectroscopic study. The expressate was collected with a platinum spatula under a slit lamp, and the pool of meibum was immediately dissolved into 0.8 mL of CDCl3 in a 9 mm microvial with a Teflon cap (Microliter Analytical Supplies, Inc, Suwanee, Georgia, USA). Argon gas was blown over the samples to prevent oxidation. The sample in the vial was capped and frozen under argon gas until analysis. Each eye sample was collected separately. Analyses were performed within 3 weeks of collection of the sample. The samples never came in contact with any plastic to avoid plasticisers. Control CDCl3 spectra were measured to ensure no impurities were present.

NMR measurement

Spectral data were acquired using a Varian VNMR 700 MHz NMR spectrometer (Varian, Lexington, Massachusetts, USA) equipped with a 5 mm 1H[13C/15N] 13C enhanced PFG cold probe (Palo Alto, California, USA). Spectra were acquired with a minimum of 250 scans, 45° pulse width and a relaxation delay of 1,000s. All spectra were obtained at 25°C. The tetramethylsilane resonance was set to 0 ppm.

Commercial software (GRAMS 386; Galactic Industries Corp, Salem, New Hampshire, USA) was used for phasing, curve fitting and integrating.

RESULTS

Of the 14 patients who underwent plaque therapy for choroidal melanoma, 9 (64 %) were male, 13 (93 %) were Caucasian and 1 was Hispanic. The patients ages ranged from 51 to 77 years, averaging 61±9 years with a median age of 56 years. All patients had choroidal melanoma with the exception of one patient who had undergone radiotherapy for iris melanoma.

1H-NMR resonances, characteristic of human meibum, were resolved in the spectra of meibum from eye treated with radiation (figure 1). The total amount of meibum esters decreased by 80%±18% (±99% CI) in 11 eyes that were treated compared with the contralateral untreated eye. The total amount of meibum esters increased by 181% in two eyes that were treated compared with the contralateral untreated eye. The molar % CE/WE for meibum was significantly (p<0.0001) 67% lower in eyes that were irradiated compared with control eyes from donors without choroidal melanoma and were not treated26 (figure 2A). The molar % CE/WE for meibum was significantly (p=0.023) 21% lower in eyes that were irradiated compared with the contralateral untreated eye. The molar % CE/WE for meibum was significantly (p=0.0001) 38% lower in eyes that were irradiated compared with control eyes from donors that did not have choroidal melanoma and was not treated26 (figure 2A). The molar % (cholesterol plus CE)/WE for meibum was significantly (p=0.0008) different in eyes that were irradiated compared with the contralateral eye eyes that did not have uveal melanoma and was not treated (figure 2A). The molar % (cholesterol plus CE)/WE for meibum was significantly (p=0.05) different in eyes that were irradiated compared with the contralateral eye eyes that did not have uveal melanoma and was not treated (figure 2B). The intensity of the meibum cis double bond resonances near 5.4 ppm (figure 1) did not change significantly (p>0.05) relative to the WE resonance times 3 at 4 ppm plus the cholesterol resonances at 1 and 0.66 ppm (figure 1) in irradiated eyes compared with the contralateral untreated eyes 0.30±0.03 and 0.28±0.05, respectively.
DISCUSSION

Statement of principal findings

The two major findings of this study are: the amount of expressed meibum in eyes that had plaque brachytherapy was 80% lower in 11 of 14 eyes compared with the contralateral eye, and both the total cholesterol moieties and CE were lower relative to WE in meibum from eyes that had plaque brachytherapy compared with the contralateral eye that received no treatment and eyes that did not have uveal melanoma.26

Strengths and weaknesses of the study

The advantages and disadvantages of using a spectroscopic approach to study meibum compositional, and tear film structural and functional relationships have been reviewed.27 As meibum quantity and composition have never been measured in relationship to brachytherapy, the strengths and weaknesses in relation to other studies and important differences in results cannot be discussed. Future studies could be designed to determine the relationships between meibum composition and structure in relationship to the type of radioactive plaques (iodine-125, ruthenium-106, palladium-103 and so on) doses and dose rates and plaque position.

Meibum quantity

The amount of meibum on the eye lid surface reservoir may not be important to tear film stability and dry eye because for donors with meibomian seborrhoea or MGD, the amount of meibum on the eye lid surface was significantly higher as measured using infrared spectroscopy29 or a meibometer.30 Meibum quantity was discussed in
a review article concluding that the uniformity of the spread film across the ocular surface is a far more reliable indicator than the quantity of meibum. The uniformity of the spread film can be estimated as the ratio of mean thickness to the thickness SD (based on the lipid layer thickness heterogeneity across the eye). Support for this idea comes from a study where the central tear film lipid of the spread film can be estimated as the ratio of mean indicator than the quantity of meibum. The uniformity spread film across the ocular surface is a far more reliable proportion. Future studies are planned to test this idea. 

The thickness of the TFLL may also not be important to tear film stability and dry eye because TFLL thickness is not related to increased tear film breakup time or a decreased thinning as discussed below. The TFLL thickness of patients with seasonal allergic conjunctivitis was thinner than controls, yet the stability of their tear film and breakup time decreased, opposite of what one would expect. Furthermore, there was no correlation between TFLL thickness and non-invasive tear break-up time for 29 young and 86 older subjects without dry eye and 110 patients with dry eye. Although the thinning rate and TFLL was significant in one study, the correlation was rather low (r about 0.3). 

The amount of meibum expressed from the meibomian glands, as measured in the current study, could be important to tear film stability. Eyes treated with plaque brachytherapy had 80% less meibum compared with the contralateral eye. It is reasonable to speculate that with such a low amount of meibum in the gland, expression of meibum on blinking could be hindered resulting in a very thin or absent TFLL that could destabilise the tear film. It has been suggested that one needs the absence of a TFLL to observe an increase in the rate of tear evaporation. Future studies are planned to test this idea.

Meibum quality

The amount of CE was much lower in treated eyes, 0.16 CE/WE (mole/mole), and was lower compared with the amount of total cholesterol moieties ((cholesterol and CE)/WE), 0.31 mole/mole. This indicates that plaque radiation may have de-esterified the CE. In this study, both the total cholesterol moieties and CE alone were lower relative to WE in meibum from eyes that had plaque treatment compared with the contralateral eye that received no treatment and eyes that did not have choroidal or iris melanoma. It is interesting that patients with dry eye due to MGD also have lower CE/WE ratios. It is attractive to suggest that lower ratios of CE/WE contribute to an unstable tear film and dry eye or perhaps cause the eyes to be more susceptible to dry eye. However, there are a few patients that have normal CE/WE ratios and have dry eye and a few patients that have no dry eye but lower levels of CE/WE. The degree to which a low level of CE/WE contributes to dry eye or susceptibility to dry eye is under investigation. It is likely that in addition to lower levels of CE/WE, changes in the amount of other moieties such as saturation and/or proteins, phospholipids and (O-acyl)-ω-hydroxy fatty acids contribute to tear film stability. Controlled biophysical experiments studying the WE/CE impact on the properties of meibomian films are a worthy direction for further study.

In conclusion, eyes that had plaque brachytherapy had a lower amount of expressible meibum and a lower CE/WE ratio compared with meibum from the contralateral eye that received no treatment and control eyes that did not have a melanoma. Both the quality and quantity of meibum should be considered in designing a therapy for dry eye after plaque brachytherapy.

**Contributors** DB was responsible for collecting and analysing data, writing and submitting the article and funding support. SFA was responsible for collecting and analysing data and editing the manuscript. AR was responsible for designing the study, collecting samples and editing the manuscript.

**Funding** This work has received support from the National Institute of Health R01EY026180 and an unrestricted grant from Research to Prevent Blindness Inc. New York, New York, USA, G1N51619B.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** Protocols and procedures were reviewed by the University of Louisville Institutional Review Board #11.0319, August 2016. All procedures were in accordance with the Declaration of Helsinki.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Douglas Borchman http://orcid.org/0000-0003-4241-591X

**REFERENCES**

1. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684–93.
2. Nag S, Quivey JM, Earle JD, et al. The American brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003;56:544–55.
3. Al-Wassia R, Dal Pra A, Shun K, et al. Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. Int J Radiat Oncol Biol Phys 2011;81:e455–62.
4. Conway RM, Poothullil AM, Daftari IK, et al. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Arch Ophthalmol 2006;124:838–43.
5. Quivey JM, Char DH, Phillips TL, et al. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993;26:613–8.
6. Razzaq L, de Keizer RJW. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes? Br J Ophthalmol 2010;94:1549–50.
7. Heilmann H, Coupland SE, Gochman R, et al. Alterations in expression of mucin, tenascin-C and syndecan-1 in the conjunctiva following retinal surgery and plaque radiotherapy. Graefes Arch Clin Exp Ophthalmol 2001;239:488–95.
8. Karp LA, Streeter BW, Cogan DG. Radiation-Induced atrophy of the meibomian gland. Arch Ophthalmol 1979;97:303–5.
9. Kim SE, Yang HJ, Yang S-W. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal...
mucosa-associated lymphoid tissue lymphoma. 

BMC Ophthalmol 2020;20:24.

10 Green-Church KB, Butovich I, Willcox M, et al. The International workshop on meibomian gland dysfunction: report of the Subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci 2011;52:1979–93.

11 Pucker AD, Nichols JJ. Analysis of meibum and tear lipids. Ocul Surf 2012;10:230–50.

12 Butovich IA, Millar TJ, Ham BM. Understanding and analyzing meibomian lipids—a review. Curr Eye Res 2008;33:405–20.

13 Knop E, Knop N, Millar T, et al. The International workshop on meibomian gland dysfunction: report of the Subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011;52:1938–78.

14 Murtuza J. The lipid component in the XIX and XX centuries. Ocul Surf 2012;10:200–9.

15 Georgiev GA, Efimov P, Yokoi N. Structure-function relationship of tear film lipid layer: A contemporary perspective. Exp Eye Res 2017;163:17–28.

16 Mudgil P, Borchman D, Gerlach D, et al. Sebum/Meibum surface film interactions and phase transitional differences. Invest Ophthalmol Vis Sci 2016;57:2401–11.

17 Robosky LC, Wade K, Woolson D, et al. Quantitative evaluation of sebum lipid components with nuclear magnetic resonance. J Lipid Res 2008;49:686–92.

18 Shrestha RK, Borchman D, Foulks GN, et al. Analysis of the composition of lipid in human meibum from normal infants, children, adolescents, adults, and adults with meibomian gland dysfunction using 1H NMR spectroscopy. Invest Ophthalmol Vis Sci 2011;52:7350–6.

19 Borchman D, Yappert MC, Milliner SE, et al. 13C and 1H NMR ester region resonance assignments and the composition of human infant and child meibum. Exp Eye Res 2013;112:151–9.

20 Borchman D, Foulks GN, Yappert MC, et al. Differences in human meibum lipid composition with meibomian gland dysfunction using NMR and principal component analysis. Invest Ophthalmol Vis Sci 2012;53:337–47.

21 Borchman D, Foulks GN, Yappert MC, et al. Changes in human meibum lipid composition with age using nuclear magnetic resonance spectroscopy. Invest Ophthalmol Vis Sci 2012;53:475–82.

22 Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;32:44–53.

23 Ivanova S, Tonchev V, Yokoi N, et al. Surface properties of Squalene/Meibum films and NMR confirmation of squalene in tears. Int J Mol Sci 2015;16:21813–31.

24 Butovich IA, McMahon A, Wojtwicz JC, et al. Dissecting lipid metabolism in meibomian glands of humans and mice: an integrative study reveals a network of metabolic reactions not duplicated in other tissues. Biochim Biophys Acta 2016;1861:538–53.

25 Borchman D, Ramasubramanian A. Human meibum chain branching variability with age, gender and meibomian gland dysfunction. Ocul Surf 2019;17:327–35.

26 Borchman D, Ramasubramanian A, Foulks GN. Human Meibum cholesteryl and wax ester variability with age, sex, and meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2019;60:2286–93.

27 Borchman D. Lipid conformational order and the etiology of cataract and dry eye. J Lipid Res 2020. doi:10.1194/jlr.TR12000874. [Epub ahead of print: 18 Jun 2020].

28 Hetman ZA, Borchman D. Concentration dependent cholesteryl-ester and wax-ester structural relationships and meibomian gland dysfunction. Biochem Biophys Res Commun 2020;521:100732. doi:10.1016/j.bbrc.2020.100732.

29 Ashraf Z, Paeha U, Greenstone V, et al. Quantification of human sebum on skin and human meibum on the eye lid margin using Sebutape® spectroscopy and chemical analysis. Curr Eye Res 2011;36:553–62.

30 Komuro A, Yokoi N, Kinoshita S, et al. Assessment of meibomian gland function by a newly-developed laser meibometer. Adv Exp Med Biol 2002;506:17–8.

31 Suzuki S, Goto E, Dogru M, et al. Tear film lipid layer alterations in allergic conjunctivitis. Cornea 2006;25:277–80.

32 Giraldez MJ, Naroo SA, Resua CG. A preliminary investigation into the relationship between ocular surface temperature and lipid layer thickness. Cont Lens Anterior Eye 2009;32:177–80.

33 Fennier BJ, Tong L. More to stable tears than thickness of the tear film lipid layer. Invest Ophthalmol Vis Sci 2015;56:1601.

34 Finis D, Pischel N, Schrader S, et al. Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for meibomian gland dysfunction. Cornea 2013;32:1549–53.

35 King-Smith PE, Hinel EA, Nichols JJ. Application of a novel interferometric method to investigate the relation between lipid layer thickness and tear film thinning. Invest Ophthalmol Vis Sci 2010;51:2418–23.

36 Tomlinson A, Trees GR, Occhipinti JR. Tear production and evaporation in the normal eye. Oph Phy Optics 1991;11:44–7.

37 Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci 1997;74:8–13.

38 Mudgil P, Borchman D, Yappert MC, et al. Lipid order, saturation and surface property relationships: a study of human meibum saturation. Exp Eye Res 2013;116:79–85.

39 Sledge S, Henry C, Borchman D, et al. Human Meibum age, lipid-lipid interactions and lipid saturation in Meibum from infants. Int J Mol Sci 2017;18:E1862.

40 Borchman D, Yappert MC, Foulks GN. Changes in human meibum lipid with meibomian gland dysfunction using principal component analysis. Exp Eye Res 2010;91:246–56.

41 Faheem S, Kim S-H, Nguyen J, et al. Wax-estear and meibum protein, wax-β-carotene interactions in vitro using infrared spectroscopy. Exp Eye Res 2012;100:32–9.

42 Chen J, Green KB, Nichols KK. Quantitative profiling of major neutral lipid classes in human meibum by direct infusion electrospray ionization mass spectrometry. Invest Ophthalmol Vis Sci 2013;54:5730–53.

43 Butovich IA. Tear film lipids. Exp Eye Res 2013;117:4–27.